HERC1
Overview
HERC1 (HECT And RLD Domain Containing E3 Ubiquitin Protein Ligase 1) is a large E3 ubiquitin ligase. A HERC1 missense mutation (P3278S) was identified as the source of an immunogenic neoantigen that drove a validated CD8+ T cell response in a pembrolizumab exceptional responder with NSCLC, establishing HERC1 as a neoantigen-generating locus of clinical significance.
Alterations observed in the corpus
- P3278S missense mutation generated the validated HLA-A-restricted neoantigen ASNASSAAK that drove a measurable, treatment-induced CD8+ T cell response in an exceptional responder to pembrolizumab in NSCLC PMID:25765070
Cancer types (linked)
- NSCLC: HERC1 P3278S generated a validated immunogenic neoantigen in an exceptional responder to pembrolizumab PMID:25765070
Co-occurrence and mutual exclusivity
- Linked partner genes with the relationship and the paper(s) reporting it.
Therapeutic relevance
- HERC1 P3278S-derived neoantigen ASNASSAAK was validated as HLA-A-restricted and drove CD8+ T cell response in a patient achieving durable clinical benefit on pembrolizumab PMID:25765070
Open questions
- Conflicts or unresolved findings across papers.
Sources
This page was processed by crosslinker on 2026-05-14.